Huntington's disease: Clinical correlates of disability and progression

Neurology

Volumn 61, Issue 8, 2003, Pages 1085-1092

  Mahant, N ^a,c   McCusker, E A ^a   Byth, K ^b   Graham, S ^a  

^a WESTMEAD HOSPITAL   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANALYTIC METHOD; ARTICLE; CHOREA; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DISABILITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DYSTONIA; FEMALE; FOLLOW UP; FUNCTIONAL DISEASE; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; ONSET AGE; PARENT; PATIENT; PHENOTYPE; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM; SEX DIFFERENCE; WEIGHT REDUCTION;

EID: 0345327753     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000086373.32347.16     Document Type: Article

References (41)

1. Thompson PD, Berardelli A, Rothwell JC, et al. The coexistence of bradykinesia and chorea in Huntington's disease and its implications for theories of basal ganglia control of movement. Brain 1988;111:223-244.
2. Duyao M, Ambrose C, Myers R, et al. Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet 1993;4:387-392.
3. Currier RD, Jackson JF, Meydrech EF. Progression rate and age at onset are related in autosomal dominant neurologic diseases. Neurology 1982;32:907-909.
4. van Dijk JG, van der Velde EA, Roos RA, Bruyn GW. Juvenile Huntington disease. Hum Genet 1986;73:235-239.
5. Myers RH, Sax DS, Koroshetz WJ, et al. Factors associated with slow progression in Huntington's disease. Arch Neurol 1991;48:800-804.
6. Illarioshkin SN, Igarashi S, Onodera O, et al. Trinucleotide repeat length and rate of progression of Huntington's disease. Ann Neurol 1994;36:630-635.
7. Brandt J, Bylsma FW, Gross R, et al. Trinucleotide repeat length and clinical progression in Huntington's disease. Neurology 1996;46:527-531.
8. Jason GW, Suchowersky O, Pajurkova EM, et al. Cognitive manifestations of Huntington disease in relation to genetic structure and clinical onset. Arch Neurol 1997;54:1081-1088.
9. Penney JB, Jr., Vonsattel JP, MacDonald ME, Gusella JF, Myers RH. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 1997;41:689-692.
10. Foroud T, Gray J, Ivashina J, Conneally PM. Differences in duration of Huntington's disease based on age at onset. J Neurol Neurosurg Psychiatry 1999;66:52-56.
11. Kieburtz K, MacDonald M, Shih C, et al. Trinucleotide repeat length and progression of illness in Huntington's disease. J Med Genet 1994;31:872-874.
12. Feigin A, Kieburtz K, Bordwell K, et al. Functional decline in Huntington's disease. Mov Disord 1995;10:211-214.
13. Siesling S, van Vugt JP, Zwinderman KA, Kieburtz K, Roos RA. Unified Huntington's disease rating scale: a follow up. Mov Disord 1998;13:915-919.
14. Marder K, Zhao H, Myers RH, et al. Rate of functional decline in Huntington's disease. Neurology 2000;54:452-458.
15. Aylward EH, Codori AM, Rosenblatt A, et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov Disord 2000;15:552-560.
16. Kirkwood SC, Su JL, Conneally P, Foroud T. Progression of symptoms in the early and middle stages of Huntington disease. Arch Neurol 2001;58:273-278.
17. Huntington Study Group. Unified Huntington's Disease Rating Scale. Reliability and consistency. Mov Disord 1996;11:136-142.
18. Shannon KM, Raman R, Leurgans S. Primary clinical components of Huntington's disease: factor structure of the motor subscale of the Unified Huntington's Disease Rating Scale. Neurology 1999;52(suppl 2):A120. Abstract.
19. Benton AL, Hamsher K. Multilingual aphasia examination manual. Iowa City: University of Iowa, 1978.
20. Smith A. Symbol Digit Modalities Test manual. Los Angeles: Western Psychological Services, 1973.
21. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol 1935;18:643-662.
22. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-974.
23. Diggle PJ, Liang K-Y, Zeger SL. Analysis of longitudinal data. Oxford: Clarendon Press, 1994.
24. Weisberg S. Applied linear regression. New York: John Wiley and Sons, 1980.
25. Altman DG. Practical statistics for medical research. London: Chapman and Hall, 1991.
26. Gomez-Tortosa E, del Barrio A, Garcia Ruiz PJ, et al. Severity of cognitive impairment in juvenile and late-onset Huntington disease. Arch Neurol 1998;55:835-843.
27. Penney JB, Young AB, Shoulson I, et al. Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord 1990;5:93-99.
28. McCusker EA, Richards F, Sillence D, Wilson M, Trent RJ. Huntington's disease: neurological assessment of potential gene carriers presenting for predictive DNA testing. J Clin Neurosci 2000;7:38-41.
29. Kirkwood SC, Siemers E, Hodes ME, et al. Subtle changes among presymptomatic carriers of the Huntington's disease gene. J Neurol Neurosurg Psychiatry 2000;69:773-779.
30. Smith MA, Brandt J, Shadmehr R. Motor disorder in Huntington's disease begins as a dysfunction in error feedback control. Nature 2000;403:544-549.
31. Marder K, Louis ED, Parides M, et al. Longitudinal evaluation of motor signs in Huntington's disease. Neurology 2002;58(suppl 3):A333. Abstract.
32. Quarrell O, Harper PS. Clinical neurology of Huntington's disease. In: Harper PS, ed. Huntington's disease. 2nd ed. London: WB Saunders, 1996.
33. Squitieri F, Sabbadini G, Mandich P, et al. Family and molecular data for a fine analysis of age at onset in Huntington disease. Am J Med Genet 2000;95:366-373.
34. Nieuwboer A, De Weerdt W, Dom R, Lesaffre E. A frequency and correlation analysis of motor deficits in Parkinson patients. Disabil Rehabil 1998;20:142-150.
35. Beal MF. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 2000;23:298-304.
36. Pratley RE, Salbe AD, Ravussin E, Caviness JN. Higher sedentary energy expenditure in patients with Huntington's disease. Ann Neurol 2000;47:64-70.
37. Kremer HP, Roos RA, Dingjan GM, et al. The hypothalamic lateral tuberal nucleus and the characteristics of neuronal loss in Huntington's disease. Neurosci Lett 1991;132:101-104.
38. Helder DI, Kaptein AA, van Kempen GM, van Houwelingen JC, Roos RA. Impact of Huntington's disease on quality of life. Mov Disord 2001;16:325-330.
39. Thieben MJ, Duggins AJ, Good CD, et al. The distribution ofstructural neuropathology in pre-clinical Huntington's disease. Brain 2002;125:1815-1828.
40. Sanchez-Pernaute R, Kunig G, del Barrio AA, et al. Bradykinesia in early Huntington's disease. Neurology 2000;54:119-125.
41. Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001;57:397-404.